AdaptHealth (AHCO) to Release Quarterly Earnings on Tuesday

Key Points

• AdaptHealth (NASDAQ:AHCO) is set to report its Q2 2025 earnings on August 5th, with projections of earnings at $0.15 per share and revenue at $804.97 million.
• The company's shares opened at $9.59 and have a market capitalization of $1.29 billion, showing significant trading activity from institutional investors, with 82.67% of stock owned by such entities.
• Analysts maintain an average buy rating for AdaptHealth, with a price target reduced to $13.40 following assessments by Royal Bank of Canada and Truist Financial.

AdaptHealth (NASDAQ:AHCO - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect AdaptHealth to post earnings of $0.15 per share and revenue of $804.97 million for the quarter.

AdaptHealth Stock Performance

NASDAQ AHCO traded down $0.22 during trading on Friday, hitting $8.75. The company's stock had a trading volume of 1,238,704 shares, compared to its average volume of 971,071. The company has a quick ratio of 1.07, a current ratio of 1.29 and a debt-to-equity ratio of 1.25. The firm has a 50 day moving average price of $9.04 and a 200 day moving average price of $9.35. The firm has a market cap of $1.18 billion, a P/E ratio of 15.35, a price-to-earnings-growth ratio of 0.86 and a beta of 1.58. AdaptHealth has a 52 week low of $7.11 and a 52 week high of $11.70.

Analysts Set New Price Targets

Several analysts have recently weighed in on AHCO shares. Truist Financial decreased their price objective on AdaptHealth from $14.00 to $13.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Royal Bank Of Canada decreased their price target on AdaptHealth from $14.00 to $13.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, AdaptHealth presently has an average rating of "Buy" and a consensus price target of $13.40.

Hedge Funds Weigh In On AdaptHealth

A number of institutional investors and hedge funds have recently bought and sold shares of AHCO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in AdaptHealth by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company's stock worth $656,000 after purchasing an additional 2,564 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of AdaptHealth by 18.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company's stock worth $2,534,000 after acquiring an additional 35,879 shares during the last quarter. Woodline Partners LP bought a new stake in shares of AdaptHealth during the first quarter worth $2,851,000. Finally, Goldman Sachs Group Inc. raised its position in shares of AdaptHealth by 32.4% during the first quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company's stock worth $6,192,000 after acquiring an additional 139,828 shares during the last quarter. Institutional investors and hedge funds own 82.67% of the company's stock.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.